Discover an ulcerative colitis therapy to help you experience what you love, for longer†
Maintain UC remission with once—daily APRISO
APRISO is a once-daily ulcerative colitis (UC) medication indicated for the maintenance of remission of ulcerative colitis in patients aged 18 years and older. Featuring INTELLICOR® delayed—and extended—release delivery, APRISO provides long-term (up to 6 months) maintenance of remission of ulcerative colitis.
Selected Important Safety Information
You should not take APRISO® (mesalamine) extended-release capsules if you experience an allergic reaction to salicylates or aminosalicylates (sulfasalazine), or to any of the components of APRISO capsules. It is recommended that you have an evaluation of kidney function prior to treatment with APRISO therapy and periodically while on therapy. Talk to your doctor if you have any kidney or renal problems before taking APRISO.
If you have kidney or liver disease, talk to your doctor before taking APRISO. There have been reports of liver failure in patients with liver disease who have taken mesalamine.
You should not take APRISO while taking antacids because the dissolving of APRISO granules depends on pH. If you are 65 years old or older, talk to your doctor before taking APRISO. Blood cell count must be monitored closely if you are 65 or older and on mesalamine therapy. Additionally, if you have phenylketonuria (PKU), please be aware that APRISO contains 2.24 mg of phenylalanine per day.